Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL23706660 | 0.87 | TBXAS1 (0.35) | TBXAS1CYP17A1PIK3R1AKT1AKT2 | |
| SCHEMBL19997577 | 0.84 | TBXAS1 (0.46) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27683095 | 0.80 | CYP17A1 (0.43) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL19831940 | 0.78 | TBXAS1 (0.46) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27759708 | 0.78 | TBXAS1 (0.46) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27759709 | 0.78 | TBXAS1 (0.46) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27663508 | 0.78 | TBXAS1 (0.46) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| Iodide SCHEMBL28757060 | 0.78 | CYP17A1 (0.44) | TBXAS1CYP17A1CYP19A1 | |
| Bromide SCHEMBL28492540 | 0.77 | TBXAS1 (0.45) | TBXAS1CYP17A1CYP3A4CYP2D6CYP19A1 | |
| Iodide SCHEMBL28546311 | 0.76 | TBXAS1 (0.47) | TBXAS1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964790-B2 | Dye for photoelectric device and photoelectric device comprising the dye | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-06-21 | — | — | US | disclosed |
| US-7863448-B2 | Dye for photoelectronic device, photoanode comprising the dye and photoelectronic device employing the photoanode | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-01-04 | — | — | US | disclosed |
| US-20080110496-A1 | DYE FOR PHOTOELECTRIC DEVICE AND PHOTOELECTRIC DEVICE COMPRISING THE DYE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-05-15 | — | — | US | disclosed |
| US-20080087325-A1 | NOVEL DYE FOR PHOTOELECTRONIC DEVICE, PHOTOANODE COMPRISING THE DYE AND PHOTOELECTRONIC DEVICE EMPLOYING THE PHOTOANODE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080087325-A1 | NOVEL DYE FOR PHOTOELECTRONIC DEVICE, PHOTOANODE COMPRISING THE DYE AND PHOTOELECTRONIC DEVICE EMPLOYING THE PHOTOANODE | DDT, CRY1, L1CAM | TBXAS1 1794/4885CYP17A1 1138/4885CYP3A4 305/4885 |
| US-20080110496-A1 | DYE FOR PHOTOELECTRIC DEVICE AND PHOTOELECTRIC DEVICE COMPRISING THE DYE | ALAD, CACNA2D4, CACNA2D1 | TBXAS1 2144/4885CYP17A1 3514/4885CYP3A4 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.